Literature DB >> 20956637

Acral melanocytic nevi: prevalence and distribution of gross morphologic features in white and black adults.

Gary A Palicka1, Arthur R Rhodes.   

Abstract

OBJECTIVE: To determine prevalence and morphologic features of acral melanocytic nevi in white and black adults.
DESIGN: Point prevalence survey.
SETTING: Outpatient dermatology clinic. PATIENTS: Convenience sample of subjects 18 years or older. MAIN OUTCOME MEASURES: Prevalence and morphologic features based on ethnicity, sex, and age.
RESULTS: Palmar or plantar nevi were detected in 42.0% of blacks (50 of 119) vs 23.0% of whites (79 of 343) (P < .001). Palmar or plantar nevi of 6-mm diameter or larger were detected in 3.4% of blacks (4 of 119) vs 0.6% of whites (2 of 343) (P = .04). Diffusely black acral nevi were uncommon in whites (0 of 343) and blacks (1 of 119). The prevalence of palmar or plantar nevi increased directly with degree of skin pigmentation (P < .001). In whites, this prevalence was greater in women (27.1%, 51 of 188) than in men (18.1%, 28 of 155) (P = .047); in subjects younger than 50 years (30.8%, 57 of 185) than in those 50 years or older (13.9%, 22 of 158) (P < .001); in subjects with a history of atypical nevus removal than in those without (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.9-6.9); in those with at least 1 extant atypical nevus than in those without (OR, 3.2; 95% CI, 1.7-6.0); and in those with at least 20 nevi of 2-mm diameter or larger than in those without (OR, 3.0; 95% CI, 1.6-5.6).
CONCLUSIONS: Acral nevi appear to be associated with ethnicity, pigmentation, age, and cutaneous melanoma (CM) risk factors. While relatively large and/or very darkly pigmented acral nevi appear to be more common in blacks than in whites, diffusely black acral nevi are uncommon in both groups. These findings are relevant to the assessment of pigmented lesions in the differential diagnosis of acral CM.

Entities:  

Mesh:

Year:  2010        PMID: 20956637     DOI: 10.1001/archdermatol.2010.299

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Improving the diagnosis and treatment of acral melanocytic lesions.

Authors:  Maressa C Criscito; Jennifer A Stein
Journal:  Melanoma Manag       Date:  2017-05-19

2.  Features of Skin Cancer in Black Individuals: A Single-Institution Retrospective Cohort Study.

Authors:  Rachel N Manci; Megan Dauscher; Michael A Marchetti; Richard Usatine; Veronica Rotemberg; Stephen W Dusza; Ashfaq A Marghoob
Journal:  Dermatol Pract Concept       Date:  2022-04-01

Review 3.  Histologic mimics of malignant melanoma.

Authors:  Caroline Bsirini; Bruce R Smoller
Journal:  Singapore Med J       Date:  2018-05-18       Impact factor: 1.858

4.  Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II.

Authors:  Luiz Guilherme Martins Castro; Renato Marchiori Bakos; João Pedreira Duprat Neto; Flávia Vasques Bittencourt; Thais Helena Bello Di Giacomo; Sérgio Schrader Serpa; Maria Cristina de Lorenzo Messina; Walter Refkalefsky Loureiro; Ricardo Silvestre e Silva Macarenco; Hamilton Ometto Stolf; Gabriel Gontijo
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

Review 5.  Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective.

Authors:  Sanghyun Park; Sook-Jung Yun
Journal:  Dermatopathology (Basel)       Date:  2022-08-19

Review 6.  Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox.

Authors:  Alina Goldenberg; Igor Vujic; Martina Sanlorenzo; Susana Ortiz-Urda
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-08-05

7.  Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.

Authors:  Jane E Royalty; Gitte Konradsen; Ole Eskerod; Birgitte S Wulff; Birgit S Hansen
Journal:  J Clin Pharmacol       Date:  2013-11-19       Impact factor: 3.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.